Long-term results of chemoradiotherapy followed by amrubicin and cisplatin for limited-disease small cell lung cancer

Ikuo Sekine(University of Tsukuba), Tomohide Tamura(St. Luke's International Hospital), Minako Sumi(Tokyo Metropolitan Geriatric Hospital), Keiji Nihei(Osaka Medical and Pharmaceutical University), Seiji Niho(Dokkyo Medical University), Kayoko Tsujino(Hyogo Prefectural Cancer Center), Satoshi Ishikura(National Cancer Center Hospital East), Makoto Nishio(Japanese Foundation For Cancer Research), T Kozuka(Japanese Foundation For Cancer Research), Nobuyuki Yamamoto(Wakayama Medical University), Hideyuki Harada(Shizuoka Cancer Center), Miyako Satouchi(Memorial Sloan Kettering Cancer Center)
Annals of Oncology
November 1, 2015
10.1093/annonc/mdv471.79
Cited by 0

Related Papers

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
|The Lancet Oncology|2015|980